Epoetin alfa reduces blood transfusion requirements in patients with intertrochanteric fracture.
OBJECTIVE
The purpose of this study is to identify the potential benefits or complications from the use of epoetin alfa in patients with intertrochanteric fracture.


METHODS
Seventy-nine patients who sustained an intertrochanteric fracture were divided into 2 groups. One group received 10 daily doses of 20 000 IU of epoetin alfa beginning from the day of trauma, whereas the control group received placebo.


RESULTS
We found a statistically significant difference in the required units of allogenic blood used between the 2 groups (P = .034). The group that received epoetin alfa also showed an elevation of hematocrit and hemoglobin values, which was statistically significant at the seventh postoperative day (P = .019 and .015, respectively) compared to the control group. No complications were evident during our study.


CONCLUSIONS
Patients with intertrochanteric fractures seem to benefit from the use of epoetin alfa because it is safe and reduces the need for blood transfusions.
Kateros
Konstantinos
K
Department of Orthopaedics, General Hospital of Levadia, Levadia, Greece.
Sakellariou
Vasileios I
VI
Sofianos
Ioannis P
IP
Papagelopoulos
Panayiotis J
PJ
D000368:Aged; D000369:Aged, 80 and over; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006397:Hematinics / Q000627:therapeutic use*; D006400:Hematocrit / Q000706:statistics & numerical data; D006454:Hemoglobins / Q000187:drug effects; D006620:Hip Fractures / Q000097:blood / Q000628:therapy*; D006801:Humans; D008297:Male; D011184:Postoperative Period; D011994:Recombinant Proteins; D016896:Treatment Outcome
D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa